NCT06366451View on ClinicalTrials.gov

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 22, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

April 30, 2025

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
BIOLOGICAL

Rilvegostomig

Intratumoral microdose injection by the CIVO device.

BIOLOGICAL

Volrustomig

Intratumoral microdose injection by the CIVO device.

BIOLOGICAL

Sabestomig

Intratumoral microdose injection by the CIVO device.

BIOLOGICAL

AZD9592

Intratumoral microdose injection by the CIVO device.

BIOLOGICAL

Pembrolizumab

Intratumoral microdose injection by the CIVO device.

COMBINATION_PRODUCT

AZD9592 + Rilvegostomig

Intratumoral microdose injection by the CIVO device.

COMBINATION_PRODUCT

AZD9592 + Volrustomig

Intratumoral microdose injection by the CIVO device.

COMBINATION_PRODUCT

AZD9592 + Sabestomig

Intratumoral microdose injection by the CIVO device.

COMBINATION_PRODUCT

AZD9592 + Pembrolizumab

Intratumoral microdose injection by the CIVO device.

Trial Locations (7)

10467

RECRUITING

Montefiore Medical Center, The Bronx

19107

RECRUITING

University of Pennsylvania, Philadelphia

27599

RECRUITING

University of North Carolina, Chapel Hill

29406

RECRUITING

Sarah Cannon Medical Center, Charleston

29407

RECRUITING

Medical University of South Carolina, Charleston

95817

RECRUITING

UC Davis, Sacramento

97239

NOT_YET_RECRUITING

Oregon Health & Science University (OHSU), Portland

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Presage Biosciences

INDUSTRY